Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino


Autoria(s): McGlinchey, Jonathan C.P.; Tummala, Hemanth; Lester, Douglas H.
Contribuinte(s)

Abertay University. School of Science, Engineering and Technology

Data(s)

27/04/2016

27/04/2016

01/08/2016

08/03/2016

Resumo

The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension. Paradoxically the presence of the GNB3 825T allele, in exon 10, introduces a pathogenic alternative RNA splice site into the middle of exon 9. To attempt to correct this pathogenic aberrant splicing, we therefore bioinformatically designed, using a Gene Tools® algorithm, a GNB3 specific, antisense morpholino. It was hoped that this morpholino would behave in vitro as either a potential “ splice blocker and/or exon skipper, to both bind and inhibit/reduce the aberrant splicing of the GNB3, 825T allele. On transfecting a human lymphoblast cell line homozygous for the 825T allele, with this antisense morpholino, we encouragingly observed both a significant reduction (from ~58% to ~5%) in the production of the aberrant smaller GNB3 transcript, and a subsequent increase in the normal GNB3 transcript (from ~42% to ~95%). Our results demonstrate the potential use of a GNB3 specific antisense morpholino, as a pharmacogenetic therapy for essential hypertension.

Identificador

McGlinchey, j, Tummala, H. and Lester D. 2016. Correction of the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino. Nucleic Acid Therapeutics. 26(4): pp.257-265. doi: 10.1089/nat.2015.0571

2159-3345 (online)

2159-3337 (print)

http://hdl.handle.net/10373/2319

http://dx.doi.org/10.1089/nat.2015.0571

Idioma(s)

en

Publicador

Mary Ann Liebert Inc

Relação

Nucleic Acid Therapeutics, 26(4)

Direitos

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This is the accepted version of a paper published in Nucleic Acid Therapeutics © 2016 Mary Ann Liebert Inc, embargoed until 29/03/2017 to comply with the publisher's self-archiving policy.

Palavras-Chave #Antisense #Oligonucleotide #Splicing #Genomic #Gene therapy #Antisense DNA #Splicing #Gene therapy
Tipo

Journal Article

published

peer-reviewed

accepted